GFG Capital LLC Reduces Position in Zoetis Inc. (NYSE:ZTS)

GFG Capital LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 38.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,355 shares of the company’s stock after selling 843 shares during the period. GFG Capital LLC’s holdings in Zoetis were worth $265,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Asset Dedication LLC grew its stake in Zoetis by 4.8% in the second quarter. Asset Dedication LLC now owns 1,174 shares of the company’s stock valued at $204,000 after purchasing an additional 54 shares in the last quarter. Forza Wealth Management LLC raised its holdings in Zoetis by 1.8% in the 2nd quarter. Forza Wealth Management LLC now owns 3,313 shares of the company’s stock valued at $574,000 after acquiring an additional 58 shares in the last quarter. L. Roy Papp & Associates LLP increased its stake in shares of Zoetis by 2.8% in the 2nd quarter. L. Roy Papp & Associates LLP now owns 2,221 shares of the company’s stock valued at $385,000 after purchasing an additional 60 shares during the last quarter. Grove Bank & Trust increased its stake in shares of Zoetis by 0.5% in the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock valued at $2,298,000 after purchasing an additional 61 shares during the last quarter. Finally, Angeles Wealth Management LLC increased its stake in shares of Zoetis by 3.8% in the 1st quarter. Angeles Wealth Management LLC now owns 1,702 shares of the company’s stock valued at $288,000 after purchasing an additional 62 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $189.45 on Tuesday. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $86.45 billion, a price-to-earnings ratio of 36.50, a PEG ratio of 3.00 and a beta of 0.89. The firm’s 50-day moving average is $189.09 and its 200 day moving average is $177.34. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. Zoetis’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.41 earnings per share. Research analysts predict that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.91%. Zoetis’s dividend payout ratio is presently 33.14%.

Analyst Ratings Changes

A number of equities research analysts have commented on ZTS shares. Stifel Nicolaus upped their price target on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. BTIG Research increased their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Piper Sandler increased their target price on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.